Our Team

We’ve brought together commercial leaders, researchers and biotechnology experts that will transform therapeutics development.

AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including:

post-surgical pain management
cancer
other hard-to-reach targets

We’re developing products at the intersection of biomaterials and pharmaceuticals.

Senior Management Team

Dr. Mike Cooke

Co-Founder & CEO

PhD

Biomedical Engineer
Polymer design and drug delivery expert

Dr. Molly Shoichet

Co-Founder & Chief Science Officer

PhD

Chemical & Biomedical Engineer
Polymer design and drug delivery expert

Mike Foorer

Vice President Business Development & General Manager

25 years experience in drug delivery & sterile injectable manufacturing

Board of Directors

In addition to co-founders Mike Cooke and Molly Shoichet, our board is made up of the following:

Lu Han

Partner, Lumira Ventures

BSc, PhD

Michelle Scarborough

Managing Partner,
Strategic Investments and Women in Technology Fund, BDC

PhD

Sara Secall

Partner & Life Sciences Investment Director, Inveready Asset Management

Yinghong Gao

Venture Partner, Viva BioInnovator

Recent News

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

November 28th, 2023 Press Release

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more

New study setting the stage for non-opioid analgesic in post-surgical pain management

July 5th, 2023 Press Release

AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more

AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform

March 9th, 2023 Press Release

AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more

See All Recent News